China Shineway Pharmaceutical Group Limited
CSWYYOTCHealthcare● Active
$19.25
+$0.00(+0.00%)
Market Cap$36353625
P/E Ratio—
52W High$22.54
52W Low$19.25
China Shineway Pharmaceutical Group Limited (CSWYY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CSWYY · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.05B | $3.78B | $4.52B | $4.02B | $3.18B |
| Cost of Revenue | $0.85B | $0.95B | $1.12B | $1.01B | $0.81B |
| Gross Profit | $2.20B | $2.83B | $3.39B | $2.94B | $2.41B |
| Gross Margin %(computed) | 72.28% | 74.95% | 75.15% | 73.09% | 75.75% |
| Operating Expenses | |||||
| R&D Expenses | $0.10B | $0.10B | $0.11B | $0.12B | $0.11B |
| G&A Expenses | $0.00B | $0.29B | $0.33B | $0.28B | $0.26B |
| Total Operating Expenses | $1.54B | $1.99B | $2.42B | $2.22B | $1.85B |
| Operating Income | $0.66B | $0.84B | $0.98B | $0.73B | $0.53B |
| Operating Margin %(computed) | 21.75% | 22.30% | 21.60% | 18.06% | 16.58% |
| Interest Income | $0.21B | $0.18B | $0.10B | $0.09B | $0.10B |
| Interest Expense | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $1.23B | $1.15B | $1.24B | $0.93B | $0.71B |
| Income Tax Expense | $0.31B | $0.31B | $0.27B | $0.19B | $0.16B |
| Net Income | $0.92B | $0.84B | $0.97B | $0.72B | $0.56B |
| Net Margin %(computed) | 30.30% | 22.24% | 21.47% | 17.98% | 17.50% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $489.40 | $444.00 | $512.20 | $384.00 | $296.00 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | $0.73B | $1.22B | $1.42B | $1.10B | $0.90B |
| EBITDA Margin %(computed) | 24.01% | 32.31% | 31.44% | 27.45% | 28.40% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · B
Explore more China Shineway Pharmaceutical Group Limited data
About China Shineway Pharmaceutical Group Limited (CSWYY) Income Statement
China Shineway Pharmaceutical Group Limited (CSWYY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CSWYY reported revenue of $3.05B, gross profit of $2.20B (gross margin 72.28%), and net income of $0.92B — a net profit margin of 30.30%.
Frequently asked questions
CSWYY · 4 questionsChina Shineway Pharmaceutical Group Limited (CSWYY) reported revenue of $3.05B for 2025, down 19.3% year-over-year.
CSWYY revenueCSWYY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09